In-vitro image of HER2 positive cancer cells (SKBR3) exposed to HER2-Affibody-Dylight750 in (A–C) PBS and (D–F) cell culture with 10% FBS.Ardeshirpour, YasamanChernomordik, VictorZielinski, RafalCapala, JacekGriffiths, GaryVasalatiy, ...
Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancerdoi:10.3390/cimb46030171Kokot, AnnaGadakh, SachinSaha, IndrajitGajda, Ewaaniewski, MichaRakshit, SomnathSengupta, Kaustav
e13051#Background:Neoadjuvant chemotherapy (ChT) with targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)- positive breast cancer (BC). In this context, Trastuzumab (Tz) and ChT significantly improved the pathological complete response (pCR) rate. Tz and ...
HER2MenadioneNotch1Oxidative stressSKBR3 cellsTrastuzumabGiven that HER2 serves as a putative target for therapy in HER2-positive breast cancer, intrinsic and/or acquired resistance to trastuzumab (T) has been proposed to be the major obstacle in treatments. In addition, chemoresistance is commonly ...
Amentoflavone was found to be effective in suppressing FASN expression in HER2-positive SKBR3 cells. Pharmacological inhibition of FASN by amentoflavone specifically down-regulated HER2 protein and mRNA, and caused an up-regulation of PEA3, a transcriptional repressor of HER2. In addition, ...
Background: HER2-targeted therapy with the monoclonal antibody trastuzumab (HerceptinH) has improved disease-free survival for women diagnosed with HER2-positive breast cancers; however, treatment resistance and disease progression are not uncommon. Current data suggest that resistance to treatment in ...
The problematic issue in treatment of HER2 positive breast cancer cells is commonly the induction of resistance to trastuzumab which might be due to modulation of some vital signaling elements such as Notch1 and Pin1. In this study, we were aimed to investigate whether the cross talk between ...
HER2 positive breast cancerAMINO acid sequenceDRUG receptorsSOLID-phase synthesisBREAST cancerAmong the known breast cancers, the subtype with HER2 receptors-overexpressing cells is associated with a poor prognosis. The adopted monoclonal antibody Trastuzumab has improved clinical outcomes, but it is ...
Abbas, N., et al., Radioimmunotherapy of Mice with HER-2 Positive SKOV-3 Xenografts Using Th-227- and Lu-177-labeled p-benzyl- DOTA-trastuzumab. European Journal of Nuclear Medicine and Molecular Imaging, 2010. 37: p. S314-S314.